Murray A. Skinner

Worthing, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Microcrystalline tyrosine as a novel depot-forming agent in venom immunotherapy: a pre-clinical evaluation in bee-venom allergic mice.

Microcrystalline tyrosine as a novel depot-forming agent in venom immunotherapy: a pre-clinical evaluation in bee-venom allergic mice.

Journal: Frontiers in allergy
Published: March 27, 2026

The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based Approach.

The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based Approach.

Journal: Allergy
Published: April 16, 2025

Meta-Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials.

Meta-Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials.

Journal: Allergy
Published: December 24, 2024

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.

Journal: Allergy
Published: September 16, 2024

Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study.

Modulation of Cellular, Molecular, and Humoral Responses by PQ Grass 27,600 SU for the Treatment of Seasonal Allergic Rhinitis: A Randomised Double Blind Placebo Control Exploratory Field Study.

Journal: Allergy
Published: August 23, 2024

Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals.

Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals.

Journal: The Journal of allergy and clinical immunology
Published: March 01, 2024

Response to Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy".

Response to Correspondence to "Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy".

Journal: Allergy
Published: December 04, 2023

Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy.

Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: July 14, 2023

Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy.

Influence of antigen density and TLR ligands on preclinical efficacy of a VLP-based vaccine against peanut allergy.

Journal: Allergy
Published: March 27, 2023

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.

Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy.

Journal: Allergy
Published: February 17, 2023

The next generation virus-like particle platform for the treatment of peanut allergy.

The next generation virus-like particle platform for the treatment of peanut allergy.

Journal: Allergy
Published: August 09, 2022

In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma.

In situ delivery of nanoparticles formulated with micron-sized crystals protects from murine melanoma.

Journal: Journal for immunotherapy of cancer
Published: August 09, 2022
Showing 1-12 of 39

Last Updated: 09/26/2026